SLV213 Treatment in Ambulatory COVID-19 Patients

NCT04843787 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

81

Enrollment

INDUSTRY

Sponsor class

Conditions

Covid19

Interventions

DRUG: SLV213
DRUG: SLV213
DRUG: SLV213
DRUG: Placebo
DRUG: Placebo
DRUG: Placebo

Sponsor

Kenneth Krantz, MD, PhD

Collaborators

[object Object]